Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept for prevention of flares in systemic lupus erythematosus after a recent flare
NL-OMON39295Phase 3Active, not recruiting
- Sponsor
- Merck Serono
- Start
- Jun 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Atacicept with Placebo (2 arms). Primary endpoint: Proportion of subjects experiencing a new flare during 52 weeks. Started Jun 2008; status: active, not recruiting.
02
Drugs
atacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON39295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39295.